GlassScriptPhysician profile
Andrew L Call
NPI 1952355794
$1,285.38
in general payments reported to CMS, 2019-2025
19 companies · $39.88 in 2025
The $39.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.82 · 2021: $45.81 · 2023: $617 · 2024: $555 · 2025: $39.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $167.45 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $141.86 | 2023-2024 | |
| Novo Nordisk INC | $136.99 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $124.88 | 2023-2024 | |
| Abbott Laboratories | $100.94 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $84.73 | 2023-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.80 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $70.18 | 2019-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $64.22 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $54.92 | 2023-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $40.20 | 2023-2024 | Rexulti |
| Amgen INC. | $39.52 | 2023-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $38.15 | 2023-2024 | Gardasil, Gardasil 9, Belsomra |
| Abbvie INC. | $35.96 | 2024 | |
| Exact Sciences Corporation | $34.50 | 2023-2024 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $26.56 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.04 | 2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $13.28 | 2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $13.20 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.